Experienced in Hepatorenal Syndrome

Dr. Charles S. Landis

Hepatology
Kaiser Permanente
Kaiser Permanente Specialty Center Gastroenterology
125 16th Avenue East, Suite CSB-2, 
Seattle, WA 
Experienced in Hepatorenal Syndrome
Kaiser Permanente
Kaiser Permanente Specialty Center Gastroenterology
125 16th Avenue East, Suite CSB-2, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Charles Landis is a Hepatologist in Seattle, Washington. Dr. Landis is rated as an Experienced provider by MediFind in the treatment of Hepatorenal Syndrome. His top areas of expertise are Hepatitis C, Hepatitis, Sclerosing Cholangitis, Cholangitis, and Liver Transplant.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hepatorenal Syndrome.

Specialties
Hepatology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO

Locations

Kaiser Permanente Specialty Center Gastroenterology
125 16th Avenue East, Suite CSB-2, Seattle, WA 98112

Additional Areas of Focus

Dr. Landis has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Other
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: January 29, 2025
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: March 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Drug
Study Phase: Phase 2
An Observational Study of Patients With Coronavirus Disease 2019
An Observational Study of Patients With Coronavirus Disease 2019
Enrollment Status: Unknown
Publish Date: January 18, 2022
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Enrollment Status: Withdrawn
Publish Date: August 30, 2021
Intervention Type: Drug, Device
Study Phase: Early Phase 1
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
Enrollment Status: Terminated
Publish Date: August 09, 2021
Intervention Type: Combination product
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Enrollment Status: Completed
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Enrollment Status: Unknown
Publish Date: December 13, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 21 Less Clinical Trials

49 Total Publications

Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes.
Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: April 02, 2025
Similar Doctors
Experienced in Hepatorenal Syndrome
Dr. Pankaj Rajvanshi
Hepatology
Experienced in Hepatorenal Syndrome
Dr. Pankaj Rajvanshi
Hepatology

Valley Medical Group-Renton

4011 Talbot Rd S, Suite 500, 
Renton, WA 
 (13.5 miles away)
425-690-3488
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pankaj Rajvanshi is a Hepatologist in Renton, Washington. Dr. Rajvanshi is rated as an Advanced provider by MediFind in the treatment of Hepatorenal Syndrome. His top areas of expertise are Intestinal Cancer, Alcoholic Cirrhosis, Visceromegaly, Jaundice, and Endoscopy.

Experienced in Hepatorenal Syndrome
Dr. Aalam S. Sohal
Hepatology
Experienced in Hepatorenal Syndrome
Dr. Aalam S. Sohal
Hepatology
3216 Ne 45th Pl Ste 212, 
Seattle, WA 
 (1.9 miles away)
206-536-3030
Languages Spoken:
English
See accepted insurances

Aalam Sohal is a Hepatologist in Seattle, Washington. Dr. Sohal is rated as an Advanced provider by MediFind in the treatment of Hepatorenal Syndrome. His top areas of expertise are Cholangitis, Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Transplant, and Endoscopy.

Experienced in Hepatorenal Syndrome
Dr. Calvin Kiani
Hepatology
Experienced in Hepatorenal Syndrome
Dr. Calvin Kiani
Hepatology

Swedish Health Services

21600 Hwy 99, Suite 150, 
Edmonds, WA 
 (11.9 miles away)
425-673-3380
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Calvin Kiani is a Hepatologist in Edmonds, Washington. Dr. Kiani is rated as an Experienced provider by MediFind in the treatment of Hepatorenal Syndrome. His top areas of expertise are Hepatitis, Hepatitis C, Hepatorenal Syndrome, and Alcoholic Cirrhosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Landis's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile